Endologix (NASDAQ:ELGX) and Restoration Robotics (NASDAQ:HAIR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
This table compares Endologix and Restoration Robotics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Endologix and Restoration Robotics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endologix presently has a consensus target price of $3.86, indicating a potential upside of 155.44%. Restoration Robotics has a consensus target price of $9.00, indicating a potential upside of 320.56%. Given Restoration Robotics’ stronger consensus rating and higher possible upside, analysts clearly believe Restoration Robotics is more favorable than Endologix.
Valuation and Earnings
This table compares Endologix and Restoration Robotics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Endologix||$181.16 million||0.71||-$66.40 million||($0.48)||-3.15|
|Restoration Robotics||$21.30 million||2.93||-$17.84 million||($2.50)||-0.86|
Restoration Robotics has lower revenue, but higher earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than Restoration Robotics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
94.0% of Endologix shares are held by institutional investors. Comparatively, 29.7% of Restoration Robotics shares are held by institutional investors. 4.1% of Endologix shares are held by company insiders. Comparatively, 37.8% of Restoration Robotics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Restoration Robotics beats Endologix on 8 of the 13 factors compared between the two stocks.
Endologix Company Profile
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Restoration Robotics Company Profile
Restoration Robotics, Inc., a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. The company offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. Its system includes the ARTAS Hair Studio application, an interactive three-dimensional patient consultation tool that enables a physician to create a simulated hair transplant model for use in patient consultations. The company was founded in 2002 and is headquartered in San Jose, California.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.